$63m for allosteric modulators for neurological disorders


Neurosterix has launched with a $63 million Series A financing led by Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures.

The company will acquire Addex’s allosteric modulator discovery technology platform. The platform has a track record of identifying highly selective, brain penetrant small molecule drugs, a class that has the potential to revolutionise the treatment of neurological disorders.

“We are excited to launch Neurosterix with the support of our founding investors, Perceptive Advisors and Acorn Bioventures, to rapidly advance our pipeline of potentially best-in-class therapies targeting patients who suffer from debilitating neurological disorders,” said Tim Dyer, CEO of Neurosterix. “Our goal at Neurosterix is to develop new medicines based on allosteric modulation that overcome the burdens of traditional drugs and provide patients with the potential to dramatically improve their lives.”

Neurosterix’s lead programme is a muscarinic acetylcholine receptor subtype 4 positive allosteric modulator (M4 PAM) for the treatment of patients suffering from schizophrenia.

Allosteric modulators bind to their target receptor outside of the active site, where the natural ligand and traditional drugs operate. This non-competitive mode of action brings greater selectivity and more precision over the control of biological pathways, potentially delivering improved efficacy and safety.

“We are dedicated to supporting the Neurosterix team in its development of these promising assets and will provide the necessary resources to enable the company to rapidly advance transformational therapies for patients struggling from neurological disorders,” said Fred Callori, Managing Director, Venture at Perceptive Advisors and Chairman of the Board of Neurosterix. “We recognise the potential of not only the assets now being developed within Neurosterix, but also the potential of the platform to develop a broad-based set of life-changing medicines.”

Diana Spencer, Senior Digital Content Editor, DDW

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free